BG
KRTX

Bellevue Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bellevue Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,100
Closed -$1.93M – 182
2023
Q4 		$1.93M Sell
6,100
-800
-12% -$156K 0.03% 107
2023
Q3 		$1.17M Sell
6,900
-3,200
-32% -$602K 0.02% 123
2023
Q2 		$2.19M Buy
10,100
+2,800
+38% +$600K 0.03% 112
2023
Q1 		$1.33M Hold
7,300
– – 0.02% 123
2022
Q4 		$1.43M Buy
+7,300
New +$1.57M 0.02% 130

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Bellevue Group's KRTX Position: Q1 2024 in Review

Bellevue Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 6,100 shares — an estimated $1.93M sold.

Bellevue Group first reported a position in KRTX in Q4 2022 and held it in 5 quarters. The position peaked at $2.19M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Bellevue Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bellevue Group sold 6,100 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.93M.
  • Bellevue Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
  • Bellevue Group's Karuna Therapeutics, Inc. Common Stock position peaked at $2.19M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.